REMEMBER THAT WE ARE NOW A PHASE III COMPANY
Current market cap 162 mil US, - we are 1.38 from NYSE uplisting requirements
- we are 2.38 from Nasdaq uplisting requirements
We are waiting on Phase III Human Clinical Trial Health Canada Approval a 20 billion a year unmet market.
- BLU is currently 795 mil market cap for Chronic Cough (Phase 2)
- VXRT is currently 888 mil market cap US Oral Vaccines
- SAVA is 2 billion US market cap for Blood Cancer (Phase 2)
- CYDY is 1.1 billion US market cap for Antibodies
- TRIL was 2.2 billion buyout (Phase 2)
-
We recieved positive Phase II data, enough for the governement to fully fund Phase III/ there is no reason why we are not at a 695 million market cap of
$11.20 on the low side and $35 on the high end. We have fully patented new mechanism of action with a drug library. IMHO we will be 10x this current price if data deems it worthy.